Skip to main content
. 2020 Jan 23;17(2):474–480. doi: 10.5114/aoms.2020.92572

Table I.

Clinical and demographic characteristics of small cell lung cancer patients

Parameter Value
Gender, n (%):
 Male 65 (63)
 Female 38 (37)
Age:
 Age median ± SD [years]: 64 ±7.5
 ≥ 64, n (%) 48 (46.6)
 < 64, n (%) 55 (53.4)
Environmental/occupational exposure to carcinogens, n (%):
 Yes 34 (33)
 No 69 (67)
Smoking status, n (%):
 Current smokers 9 (8.7)
 Former smokers 89 (86.4)
 Non-smokers 4 (4.9)
Smoking intensity, n (%):
 Light smoker (< 15 pack-years) 23 (23)
 Heavy smoker (> 15 pack-years) 77 (77)
Performance status, n (%):
 0 25 (24.3)
 1 51 (49.5)
 2 27 (26.2)
 3 0 (0)
TNM, n (%):
 I 3 (2.9)
 II 11 (10.7)
 III 30 (29.1)
 IV 59 (57.3)
Distant metastases, n (%):
 Yes 63 (61.1)
 No 40 (38.9)
Response to platinum-based chemotherapy, n (%):
 PD 12 (11.7)
 SD 53 (51.5)
 PR 37 (35.9)
 CR 1 (0.9)
Weight loss during chemotherapy (any grade), n (%):
 Yes 27 (26.2)
 No 76 (73.8)
Neutropenia during chemotherapy (any grade), n (%):
 Yes 55 (53.4)
 No 48 (46.6)
Anaemia during chemotherapy (any grade), n (%):
 Yes 52 (50.5)
 No 51 (49.5)
Radiotherapy, n (%):
 Yes 58 (56.3)
 No 45 (43.7)
Treatment regimen:
 Cisplatin + etoposide 101 (98)
 Carboplatin + etoposide 2 (2)
Chemotherapy (no. of cycles):
 1 4 (3.9)
 2 9 (8.7)
 3 4 (3.9)
 4 21 (20.4)
 5 13 (12.6)
 6 52 (50.5)

PD – progression of disease, SD – stable disease, PR – partial remission, CR – complete remission.